Your browser doesn't support javascript.
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Wratil, Paul R; Stern, Marcel; Priller, Alina; Willmann, Annika; Almanzar, Giovanni; Vogel, Emanuel; Feuerherd, Martin; Cheng, Cho-Chin; Yazici, Sarah; Christa, Catharina; Jeske, Samuel; Lupoli, Gaia; Vogt, Tim; Albanese, Manuel; Mejías-Pérez, Ernesto; Bauernfried, Stefan; Graf, Natalia; Mijocevic, Hrvoje; Vu, Martin; Tinnefeld, Kathrin; Wettengel, Jochen; Hoffmann, Dieter; Muenchhoff, Maximilian; Daechert, Christopher; Mairhofer, Helga; Krebs, Stefan; Fingerle, Volker; Graf, Alexander; Steininger, Philipp; Blum, Helmut; Hornung, Veit; Liebl, Bernhard; Überla, Klaus; Prelog, Martina; Knolle, Percy; Keppler, Oliver T; Protzer, Ulrike.
  • Wratil PR; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Stern M; German Centre for Infection Research (DZIF), Partner Site, Munich, Germany.
  • Priller A; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Willmann A; Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich (TUM), School of Medicine, Munich, Germany.
  • Almanzar G; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Vogel E; Pediatric Rheumatology / Special Immunology, Pediatrics Department, University Hospital Würzburg, Würzburg, Germany.
  • Feuerherd M; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Cheng CC; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Yazici S; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Christa C; Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich (TUM), School of Medicine, Munich, Germany.
  • Jeske S; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Lupoli G; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Vogt T; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Albanese M; Pediatric Rheumatology / Special Immunology, Pediatrics Department, University Hospital Würzburg, Würzburg, Germany.
  • Mejías-Pérez E; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Bauernfried S; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Graf N; Gene Center and Department of Biochemistry, LMU München, Munich, Germany.
  • Mijocevic H; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Vu M; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Tinnefeld K; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Wettengel J; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Hoffmann D; German Centre for Infection Research (DZIF), Partner Site, Munich, Germany.
  • Muenchhoff M; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Daechert C; German Centre for Infection Research (DZIF), Partner Site, Munich, Germany.
  • Mairhofer H; Institute of Virology, Helmholtz Center Munich, TUM, School of Medicine, Munich, Germany.
  • Krebs S; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Fingerle V; German Centre for Infection Research (DZIF), Partner Site, Munich, Germany.
  • Graf A; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Steininger P; Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
  • Blum H; Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.
  • Hornung V; Bavarian Health and Food Safety Authority (LGL), Oberschleißheim, Germany.
  • Liebl B; Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.
  • Überla K; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Prelog M; Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.
  • Knolle P; Gene Center and Department of Biochemistry, LMU München, Munich, Germany.
  • Keppler OT; Bavarian Health and Food Safety Authority (LGL), Oberschleißheim, Germany.
  • Protzer U; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Nat Med ; 28(3): 496-503, 2022 03.
Article in English | MEDLINE | ID: covidwho-1655606
ABSTRACT
Infection-neutralizing antibody responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 vaccination are an essential component of antiviral immunity. Antibody-mediated protection is challenged by the emergence of SARS-CoV-2 variants of concern (VoCs) with immune escape properties, such as omicron (B.1.1.529), which is rapidly spreading worldwide. Here we report neutralizing antibody dynamics in a longitudinal cohort of coronavirus disease 2019 convalescent and infection-naive individuals vaccinated with mRNA BNT162b2 by quantifying SARS-CoV-2 spike protein antibodies and determining their avidity and neutralization capacity in serum. Using live-virus neutralization assays, we show that a superior infection-neutralizing capacity against all VoCs, including omicron, developed after either two vaccinations in convalescents or a third vaccination or breakthrough infection of twice-vaccinated, naive individuals. These three consecutive spike antigen exposures resulted in an increasing neutralization capacity per anti-spike antibody unit and were paralleled by stepwise increases in antibody avidity. We conclude that an infection-plus-vaccination-induced hybrid immunity or a triple immunization can induce high-quality antibodies with superior neutralization capacity against VoCs, including omicron.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-01715-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-01715-4